Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 11/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1399553 | 1.00 | HCRTR2 (0.37) | HCRTR2ALDH1A1LMNAMAPTCYP2C9 | |
| SCHEMBL1399596 | 0.86 | HCRTR2 (0.38) | HCRTR2ALDH1A1LMNAMAPTCYP2C9 | |
| SCHEMBL1399597 | 0.86 | HCRTR2 (0.38) | HCRTR2ALDH1A1LMNAMAPTCYP2C9 | |
| SCHEMBL14113476 | 0.86 | HCRTR2 (0.38) | HCRTR2ALDH1A1LMNAMAPTCYP2C9 | |
| SCHEMBL1399650 | 0.81 | ALDH1A1 (0.39) | HCRTR2ALDH1A1MAPT | |
| SCHEMBL1399648 | 0.81 | ALDH1A1 (0.39) | HCRTR2ALDH1A1MAPT | |
| SCHEMBL3307324 | 0.81 | ALDH1A1 (0.50) | ALDH1A1LMNAMAPTCYP2C9DGAT1 | |
| SCHEMBL25468869 | 0.79 | TSHR (0.50) | HCRTR2ALDH1A1LMNAMAPT | |
| SCHEMBL1399763 | 0.78 | OPRM1 (0.41) | HCRTR2ALDH1A1LMNA | |
| SCHEMBL1399761 | 0.78 | OPRM1 (0.41) | HCRTR2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2035417-B1 | BENZIMIDAZOLES AND THEIR USE FOR THE TREATEMNT OF DIABETES | ASTRAZENECA AB (SE) | 2011-03-02 | — | — | EP | disclosed |
| EP-2035417-B1 | BENZIMIDAZOLES AND THEIR USE FOR THE TREATEMNT OF DIABETES | ASTRAZENECA AB (SE) | 2011-03-02 | — | — | EP | disclosed |
| US-20090197926-A1 | BENZIMIDAZOLES AND THEIR USE FOR THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2009-08-06 | — | — | US | disclosed |
| US-20090197926-A1 | BENZIMIDAZOLES AND THEIR USE FOR THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2009-08-06 | — | — | US | disclosed |
| US-20090197926-A1 | BENZIMIDAZOLES AND THEIR USE FOR THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197926-A1 | BENZIMIDAZOLES AND THEIR USE FOR THE TREATMENT OF DIABETES | DGAT1, ACAT1, DGAT2 | HCRTR2 2310/4885ALDH1A1 112/4885LMNA 3400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.